首页> 美国卫生研究院文献>Molecules >Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review
【2h】

Recent Advances in Polymer Nanomaterials for Drug Delivery of Adjuvants in Colorectal Cancer Treatment: A Scientific-Technological Analysis and Review

机译:高分子纳米材料在大肠癌治疗中辅助药物给药的最新进展:科学技术分析与评论

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Colorectal cancer (CRC) is the type with the second highest morbidity. Recently, a great number of bioactive compounds and encapsulation techniques have been developed. Thus, this paper aims to review the drug delivery strategies for chemotherapy adjuvant treatments for CRC, including an initial scientific-technological analysis of the papers and patents related to cancer, CRC, and adjuvant treatments. For 2018, a total of 167,366 cancer-related papers and 306,240 patents were found. Adjuvant treatments represented 39.3% of the total CRC patents, indicating the importance of adjuvants in the prognosis of patients. Chemotherapy adjuvants can be divided into two groups, natural and synthetic (5-fluorouracil and derivatives). Both groups can be encapsulated using polymers. Polymer-based drug delivery systems can be classified according to polymer nature. From those, anionic polymers have garnered the most attention, because they are pH responsive. The use of polymers tailors the desorption profile, improving drug bioavailability and enhancing the local treatment of CRC via oral administration. Finally, it can be concluded that antioxidants are emerging compounds that can complement today’s chemotherapy treatments. In the long term, encapsulated antioxidants will replace synthetic drugs and will play an important role in curing CRC.
机译:大肠癌(CRC)是第二高的发病率类型。最近,已经开发了许多生物活性化合物和包囊技术。因此,本文旨在综述CRC化疗辅助治疗的药物输送策略,包括对与癌症,CRC和辅助治疗相关的论文和专利的初步科学技术分析。 2018年,共发现167,366篇与癌症相关的论文和306,240项专利。辅助治疗占CRC专利总数的39.3%,表明辅助剂在患者预后中的重要性。化学治疗佐剂可分为天然和合成两组(5-氟尿嘧啶及其衍生物)。两组均可使用聚合物包封。基于聚合物的药物递送系统可以根据聚合物的性质进行分类。从这些中,阴离子聚合物引起了最多的关注,因为它们具有pH响应能力。聚合物的使用可调整解吸曲线,改善药物的生物利用度,并通过口服给药增强CRC的局部治疗。最后,可以得出结论,抗氧化剂是新兴的化合物,可以补充当今的化学疗法。从长远来看,封装的抗氧化剂将替代合成药物,并在治愈CRC中起重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号